Latest Research

In a recent study published in Biochemical Society Transactions, researchers explored multispecific nanobody technology. This breakthrough approach enhances targeted therapy by simultaneously allowing a single molecule to bind to multiple epitopes or antigens. Unlike traditional antibodies, multispecific nanobodies offer superior stability, specificity, and therapeutic potential in cancer and viral infections.

Plant-derived extracellular vesicles (EVs) have emerged as a powerful tool in cancer drug delivery. A recent study published in Nature Materials (2024) sheds light on the advantages of using these natural carriers for targeted therapies, addressing a critical need in oncology for more effective, non-toxic delivery systems.

Breast cancer remains a major challenge in oncology, requiring targeted therapies that enhance tumor specificity while minimizing systemic toxicity. Monoclonal antibodies (mAbs) have shown promise, but their large size (~150 kDa), high cost, and limited tumor penetration present obstacles in treatment.